|
Exploratory Study of Personalized mRNA Vaccine in Patients With Refractory Rhabdomyosarcoma
RECRUITINGEarly 1Sponsored by Xinxin Zhang
Actively Recruiting
PhaseEarly 1
SponsorXinxin Zhang
Started2025-10-13
Est. completion2027-05-01
Eligibility
Age6 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06932861
Summary
An Exploratory Study on the Use of mRNA Tumor Vaccines in the Treatment of Refractory Rhabdomyosarcoma
Eligibility
Age: 6 Years+Healthy volunteers accepted
Inclusion Criteria: 1. Diagnosed with rhabdomyosarcoma confirmed by pathological or molecular testing; 2. Age ≥ 6 years; 3. Has residual tumor or minor disease progression following standard therapy, and has no available effective treatment option. (\*: Prior to vaccine administration, during the vaccine manufacturing period, continuation of the prior antitumor regimen is permitted in combination with the study drug(s).) 4. Expected survival time greater than 6 months; 5. ECOG performance status score of 0-1; - Exclusion Criteria: * 1.History of or concurrent with other untreated malignant tumors, except for previously cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and superficial bladder cancer; 2.History of or current active autoimmune diseases. 3.Has uncontrolled cardiovascular diseases.
Conditions2
CancerRhabdomyosarcoma
Interventions1
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseEarly 1
SponsorXinxin Zhang
Started2025-10-13
Est. completion2027-05-01
Eligibility
Age6 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06932861